Antiplatelet Therapy in Patients With Abdominal Aortic Aneurysm Without Symptomatic Atherosclerotic Disease
JAMA Network Open · 25.10.2023 · 6 (10) · e2339715
DOI: 10.1001/jamanetworkopen.2023.39715 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 25.10.2023. Verfasst von Chalotte W Nicolajsen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark. Hauptthemen laut MEDLINE: Aortic Aneurysm, Abdominal, Atherosclerosis, Ischemic Stroke, Myocardial Infarction. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Patients with abdominal aortic aneurysm have a high risk of ischemic events associated with concomitant atherosclerotic cardiovascular disease, and current clinical practice guidelines recommend antiplatelet therapy to mitigate this risk. However, in patients with aneurysms without symptomatic atherosclerosis, the benefit of antiplatelet therapy has been sparsely investigated.
Objective
To estimate the effect of antiplatelets on the risk of ischemic events and bleeding in individuals with abdominal aneurysms with no symptomatic atherosclerotic vascular disease. Design, Setting, and Participants A comparative effectiveness research study using a target trial emulation framework was performed. Population-based, cross-linked observational data from Danish national health registries containing comprehensive, individual-level information on all Danish citizens were used to evaluate patients who were antiplatelet-naive and diagnosed with abdominal aortic aneurysms, with no record of symptomatic atherosclerotic vascular disease, from January 1, 2010, through August 21, 2021. Exposure Prescription filled for aspirin or clopidogrel. Main Outcomes and Measures Risk of ischemic events (myocardial infarction and/or ischemic stroke) and risk of major bleeding. For target trial emulation, trials were emulated as sequential, contingent on patient eligibility at the time of inclusion, and were evaluated by means of pooled logistic regression models to estimate the intention-to-treat and as-treated effects, expressed as hazard ratio (HR) and event-free survival.
Results
A total of 6344 patients (65.2% men; age, 72 [IQR, 64-78] years) provided 131 047 trial cases; 3363 of these cases involved initiation of antiplatelet therapy and 127 684 did not. A total of 182 ischemic events occurred among initiators and 5602 ischemic events occurred among noninitiators, corresponding to an intention-to-treat HR of 0.91 (95% CI, 0.73-1.17) and an estimated absolute event-free survival difference of −0.6% (95% CI, −1.7% to 0.5%). After censoring nonadherent person-time, the treatment HR was 0.90 (95% CI, 0.68-1.20), with similar risk difference. For bleeding, the intention-to-treat HR was 1.26 (95% CI, 0.97-1.58) and the event-free survival difference was 1.0%. The treatment HR was 1.21 (95% CI, 0.82-1.72); the risk difference was similar. Conclusions and Relevance In this study, no evidence of effectiveness of antiplatelet therapy to lower the risk of ischemic events and a trend toward higher bleeding risk was noted. The observed differences between the treatment groups were minimal, suggesting limited clinical relevance of antiplatelet treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.
- Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark.
- Department of Vascular Surgery, Viborg Regional Hospital, Viborg, Denmark.
- Department of Vascular Surgery, Rigshospitalet, Copenhagen, Denmark.
- Institute of Clinical Medicine, Copenhagen University, Copenhagen, Denmark.
- Thrombosis Research Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Zitieren
APA
Nicolajsen, C. W., Søgaard, M., Jensen, M., Eldrup, N., Larsen, T. B., Goldhaber, S. Z., Behrendt, C. A., & Nielsen, P. B. (2023). Antiplatelet Therapy in Patients With Abdominal Aortic Aneurysm Without Symptomatic Atherosclerotic Disease. JAMA Network Open, 6(10), e2339715. https://doi.org/10.1001/jamanetworkopen.2023.39715
Vancouver
Nicolajsen CW, Søgaard M, Jensen M, Eldrup N, Larsen TB, Goldhaber SZ, et al. Antiplatelet Therapy in Patients With Abdominal Aortic Aneurysm Without Symptomatic Atherosclerotic Disease. JAMA Network Open. 2023;6(10):e2339715. doi:10.1001/jamanetworkopen.2023.39715
BibTeX
@article{Nicolajsen2023,
author = {Nicolajsen, Chalotte W and Søgaard, Mette and Jensen, Martin and Eldrup, Nikolaj and Larsen, Torben B and Goldhaber, Samuel Z and Behrendt, Christian-Alexander and Nielsen, Peter B},
title = {Antiplatelet Therapy in Patients With Abdominal Aortic Aneurysm Without Symptomatic Atherosclerotic Disease},
journal = {JAMA Network Open},
year = {2023},
volume = {6},
number = {10},
pages = {e2339715},
doi = {10.1001/jamanetworkopen.2023.39715}
}
EUVIMED